2017-09-13 20:57:56 UTC

Implementing AGA’s Newest IBD Guideline in Your Practice

Sept. 18, 2017

Experts will provide guidance around the latest IBD guidelines at the 2018 Crohn’s & Colitis Congress.™

If you treat patients with IBD, we hope you’ve reviewed our latest clinical practice guideline on the role of therapeutic drug monitoring (TDM) in the management of IBD, published in Gastroenterology. The guideline focuses on the application of TDM for biologic therapy, specifically anti-tumor necrosis factor-α (TNF) agents, and for thiopurines, and addresses questions on the risks and benefits of reactive TDM, routine proactive TDM or no TDM in guiding treatment changes. Proactive TDM is performed when patients are responding to therapy to maintain adequate serum drug concentrations and prevent loss of response or the development of anti-drug antibodies, whereas reactive TDM is performed at time of loss of response.

During the inaugural Crohn’s & Colitis Congress™, taking place Jan. 18-20 in Las Vegas, experts will help you better understand how to use TDM to optimize the dosing regimen in individual patients. During a breakout session, Proactive Therapeutic Drug Monitoring — For Whom and How?, Dr. Niels Vande Casteele plans to answer the following questions:

  • Which patients are candidates for proactive TDM?
  • When should proactive TDM be performed: during induction or maintenance therapy?
  • What serum concentration thresholds should be used when carrying out proactive TDM?
  • Should TDM be performed for all biologics?

Get up-to-speed on the latest professional guidelines — register today for the Crohn’s & Colitis Congress, a partnership between the Crohn’s & Colitis Foundation and AGA.

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

How Will Translational Advances in Pediatric IBD Affect Practices?

Oct. 17, 2017

Dr. Rosen will discuss how new findings can make a difference for pediatric IBD patients at the Crohn’s & Colitis Congress.

Apply Biomarkers to Better Target Therapies to IBD Patients

Oct. 12, 2017

Dr. Lee A. Denson will present his findings on biomarkers in Las Vegas at the Crohn’s & Colitis Congress.